Life Biosciences to Share Phase 1 ER-100 Trial Data at AAO 2026

Life Biosciences, a Boston-based biotechnology firm focused on cellular rejuvenation therapies, announced it will present interim data from an ongoing Phase 1 clinical trial of its experimental compound ER-100 at the Eyecelerator conference held alongside the American Academy of Ophthalmology annual meeting in New Orleans, Louisiana.

The presentation, scheduled for an oral session on October 8, 2026, will mark the first public disclosure of human clinical data from the trial, which is evaluating ER-100 in patients diagnosed with glaucoma, a leading cause of irreversible blindness worldwide. First-in-human data are closely watched by clinicians and investors as early indicators of a compound's safety and tolerability profile.

Read more BioCardia Submits Revised FDA Pre-Submission for Helix Catheter Approval →

Life Biosciences describes its broader research mission as developing medicines capable of reversing diseases associated with aging at the cellular level. Optic neuropathies such as glaucoma, which involve progressive deterioration of retinal ganglion cells and the optic nerve, represent a significant unmet medical need given the limited disease-modifying options currently available to patients.

The Eyecelerator forum, co-located with the AAO annual meeting, focuses specifically on emerging ophthalmic technologies and serves as a high-profile venue for early-stage clinical announcements within the eye-care investment and research community. The choice of this platform signals the company's intent to engage specialist physicians and potential partners at an early stage of development.

Continue reading at GlobeNewswire - Industry News on Financial Services